BAJAJ BROKING

Notification close image
No new Notification messages
card image
Vikram Solar IPO is Open!
Apply for the Vikram Solar IPO through UPI in just minutes.
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

0

524652

INDSWFTLTD

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

IND-SWIFT LIMITED Share Price Update

As of the latest trading session, IND-SWIFT LIMITED share price is currently at ₹ 15.7, which is up by ₹ 0.00 from its previous closing. Today, the stock has fluctuated between ₹ 14.86 and ₹ 17.82. Over the past year, IND-SWIFT LIMITED has achieved a return of -34.14 %. In the last month alone, the return has been -4.38 %. Read More...

Investment Returns

Over 1 Month -4.38% Over 3 Months 16.72% Over 6 Months 7.82% Over 1 Year -34.14%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

IND-SWIFT LIMITED fundamentals


  • Market cap (Cr)

  • P/E Ratio (TTM)

  • Beta

  • Book Value / share

  • Return on equity

    %

  • EPS (TTM)

  • Dividend yield

    %

  • Net profit/quarter (Cr)

info icon alternate text
  • Market cap (Cr)

    85.00

  • P/E Ratio (TTM)

    0.30

  • Beta

    0.46

  • Book Value / share

    -74.27

  • Return on equity

    -12.54%

  • EPS (TTM)

    1.44

  • Dividend yield

    %

  • Net profit/quarter (Cr)

    256.60

info icon alternate text

IND-SWIFT LIMITED Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Company Name Price P/E P/B Market Cap 52 Week Low/High
Company Name Price P/E P/B Market Cap 52 Week Low/High

IND-SWIFT LIMITED Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
15.70 4.80 redarrow
red-green-graph indicator
0 Bearish
16 Bullish
  • 5 Days 15.50
  • 26 Days 16.40
  • 10 Days 15.80
  • 50 Days 16.40
  • 12 Days 15.90
  • 100 Days 16.60
  • 20 Days 16.20
  • 200 Days 17.60
16.13 PIVOT

First Support

14.43

First Resistance

17.39

Second Support

13.17

Second Resistance

19.09

Third Support

11.47

Third Resistance

20.35

RSI

42.60

ADX

11.78

MACD

-0.45

Williams % R

-66.25

Commodity Channel Index (CCI)

-55.08

Date

2025-08-13

Week

15104.00

Same Day

50355.00

Month

18158.00

1 Year

0.47

3 Year

0.55

Over 1 Month

-4.38%

down

Over 1 Year

-34.14%

down

Over 3 Months

16.72%

down

Over 3 Years

16.38%

down

Over 6 Months

7.82%

down

Over 5 Years

42.84%

down

IND-SWIFT LIMITED shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Name Shares Category

News

Left Arrow
Right Arrow

IND-SWIFT LIMITED corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
21 Sep 2011 0.4 Final 23 Sep 2011 Equity shares
24 Sep 2010 0.4 Final 28 Sep 2010 Equity shares
17 Sep 2009 0.4 Final 21 Sep 2009 Equity shares
19 Sep 2008 0.4 Final 23 Sep 2008 Equity shares
21 Sep 2007 2.0 Final 25 Sep 2007 Equity shares
28 Sep 2006 0.0 Final 30 Sep 2006 Equity shares
22 Sep 2005 0.0 Final 26 Sep 2005 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
29 Apr 2005 10.0 2.0 06 May 2005

IND-SWIFT LIMITED Share Price

Ind-Swift Limited (ISL) is an India-based pharmaceutical company. The Company is engaged in the manufacturing and marketing of pharmaceutical finished dosage. The products manufactured by the company include cephalosporins, quinolones, aminoglycosides, macrolides, chloramphenicol, tetracyclines, sulphonamides, antianaerobics and anti-fungals.

The company manufactures various dosage forms, including oral solutions and suspensions; dry syrups and hard gelatin capsules; tablets; dermatologicals comprising creams, ointments, and gels; eye and ear drops; and injectables. The company, through their different divisions, markets formulations focusing on the needs of various therapeutic segments, such as diabetology, cardiovascular, anesthesiology, oncology, ophthalmology, neuropsychiatry, gynecology, pediatric, ENT, surgery, internal medicine, dermatology, urology, cardiology, and dental specialty.

Ind-Swift Limited was incorporated in June, 1986. In the year 1991, the company set up a manufacturing facility for injectables and eye/ear drops. In the year 1995, they incorporated Ind-Swift Laboratories Ltd for initiating a backward integration into the manufacturing of APIs and advanced intermediates.

In the year 1997, the company commissioned a multipurpose plant with five independent blocks erected as per US FDA standards, designed by Quara, Switzerland. In addition, they launched a Marketing Division with the name Ind-Swift Health Care.

In the year 2000, the company launched Super Specialty Division, which is focusing on Cardiology and Diabetology segments. In the year 2001, they launched Pioglitazone and Candesartan, in which the company is the second to launch this product in India. In addition, they launched Institution/Hospital Division.

In the year 2003, the company launched another division by the name Ind-Swift Biosciences. They entered into formulations export to six countries and filed patent in US for Clarithromycin.

In the year 2004, the company launched Mukur Division with focus on ophthalmology, neuropsychiatry and ENT. They launched Launched Nitazoxanide, an antidiarrhoeal drug, first time in India after successful clinical trials. In addition, they launched another division by the name Resurgence catering to the Anesthesiology and Oncology segments. The company opened first overseas office in New Jersey, USA

During the year 2004-05, the company launched combination of Nitazoxanide and Ofloxacin, with the brand name Netazox-OF, first time in Asia. They commenced commercial production in their new formulation facility at Jammu, J&K.

During the year 2005-06, the company introduced various new product ranges in the domestic market through their nine marketing divisions. The new product launches included the launch of a unique combination of the Quinoline derivative, anti-diarrheal and anti-bacterial drug that was launched for the first time in India after completion of the successful clinical trials. They also launched the new marketing division namely Institutions & Hospitals division to look after the institutional sales.

During the year, the company commissioned three new state of the art finished dosages facility at; Samba in Jammu & Kashmir; 100% EOU at Jawaharpur and an internationally benchmarked plant at Baddi in Himachal Pradesh.

During the year 2006-07, the company developed and launched 65 new products and line extension. They launched their product in Kenya and Senegal. They also launched three new marketing division to focus on marketing of products for personal healthcare, veterinary and manufacturing and marketing of products for international companies.

During the year, the company entered into licensing agreements with number of international Pharma companies for out licensing the technology of their patented products, Clarithromycin. They received approval of the Drug Authorities of Uganda and Tanzania, which will pave the way for the supply of their drugs in these countries.

During the year 2007-08, the company's manufacturing unit at Parwanoo was upgraded as per WHO standards. The Global Business Unit (ISL-GBU), commissioned in Derabassi.

In August 2007, the company commissioned a manufacturing facility at the same tax exempted zone and green plains of Baddi. This facility is for soft Gelatin Encapsultation with an annual capacity of 36 crore. In December 2007, they launched their new division 'Diagnozis' dealing in medical equipments & devices. The company also launched animal health care, which is absolutely a new concept with outsourced marketing.

Company launched a new marketing division 'NOVA' with special focus on ophthalmology, ENT and Dermatology in 2009-10.

During 2010-11, the Company launched six divisions viz GENERIC, ONCRIT, MEGASWIFT, GYNOSWIFT, Q-DEN and CARDIA SWIFT. Apart from this, it launched new product range in all the new divisions including monopolistic products.

During 2012, the Company diversified into the Dairy Business by launching a new division, which marketed under the brand name 'All Natural'.

In 2021, company established a separate OTC division and launched 2 products via, Stevia and Hangover.

In 2022-23, Company launched many new products such as Linezolid, Ticagrelor, Etoricoxib, and Diclofenac Hot gel and Four Derm ointment etc. Also , Company set up its first wholly owned subsidiary in the Republic of Kenya with the name of Indswift India Limited' in May, 2022. Further, Company also launched new products like Metalazone, Lenalidomide Anhydrous and Methotrexate in the domestic market in 2024.

Parent organization Indian Private
NSE symbol INDSWFTLTD
Founded 1986
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Ind-Swift Ltd?

Answer Field

Ind-Swift Ltd share price is for NSE ₹ 15.76 & for BSE ₹ 15.70 as on Aug 13 2025 12:00 AM.

What is the Market Cap of Ind-Swift Ltd Share?

Answer Field

The market cap of Ind-Swift Ltd for NSE ₹ 0.00 & for BSE ₹ 85.00 as on Aug 13 2025 12:00 AM.

What is the 52 Week High and Low of Ind-Swift Ltd?

Answer Field

The 52 Week High and Low of Ind-Swift Ltd for NSE is ₹ 34.70 and ₹ 12.00 and for BSE is ₹ 34.49 and ₹ 12.00.

What is 1 year return for Ind-Swift Ltd?

Answer Field

The 1 year returns on the stock has been -34.14%.

What is the P/E Ratio of Ind-Swift Ltd Share?

Answer Field

As on Aug 13 2025 12:00 AM the price-to-earnings (PE) ratio for Ind-Swift Ltd share is 0.30.

What is the PB ratio of Ind-Swift Ltd Share?

Answer Field

As on Aug 13 2025 12:00 AM, the price-to-book (PB) ratio for Ind-Swift Ltd share is -74.27.

How to Buy Ind-Swift Ltd Share?

Answer Field

You can trade in Ind-Swift Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Ind-Swift Ltd Share on Bajaj Broking App?

Answer Field

To buy Ind-Swift Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Ind-Swift Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|